10 Best Get Rich Quick Stocks to Buy Now

2. Fate Therapeutics, Inc. (NASDAQ:FATE)

Upside potential as of July 8, 2025: 422.02%

Beta (5Y Monthly): 2.23

Analysts at H.C. Wainwright have reaffirmed their Neutral rating on Fate Therapeutics, Inc. (NASDAQ:FATE), while maintaining their price target of $5.00, implying an upside potential of around 358%. This was after the company presented its T819 data on lupus at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress in Barcelona, Spain.

This study, conducted in five patients, revealed that three patients with active lupus nephritis and a history of B-cell-targeted therapy were successful in achieving a primary renal response. The data’s SLEDAI-2K scores showed significant improvement within the one-, six-and-a-half-, and twelve-month periods, indicating a positive performance.

The research firm expressed its eagerness in DORIS remissions to consider FT819 a viable commercial threat. While the early signal of activity has led Fate Therapeutics, Inc. (NASDAQ:FATE) to continue its efforts to accelerate the study, particularly by enrolling at higher doses, the company finds itself on the bleeding edge of engineered cell therapy in autoimmune disease, a market that’s anticipated to reach high levels.

Fate Therapeutics, Inc. (NASDAQ:FATE) is a California-based clinical-stage biopharmaceutical company that focuses on the development of programmed cellular immunotherapies for people living with cancer and immune disorders. Incorporated in 2007, the company is committed to improving the lives of many.